Utility of PET In the Pre-Operative Assessment of Patients With Hepatic Colorectal Metastases
|ClinicalTrials.gov Identifier: NCT00588549|
Recruitment Status : Completed
First Posted : January 8, 2008
Last Update Posted : March 19, 2009
This study aims to determine whether a test, called the PET scan, may be useful in determining if there are additional locations of cancer not otherwise detectable by other tests.
The PET scan is a nuclear medicine imaging study that measures how much radioactive sugar is used by your tumor. The study will compare pictures of the cancer from the PET scan to other x-ray exams, such as a CT scan, as well as to what your doctors find at the time of surgery. If the study results show that the PET scan gives us a good idea of what is happening to the tumor, then it may be useful in deciding which patients with colorectal metastases to the liver should be operated on and what operation should be performed.
Additionally, by comparing the results of PET scans with the other studies that will be performed as part of your care, we will try to determine which test best tells us which patient is most likely to benefit from surgery.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||204 participants|
|Official Title:||Utility of Whole-Body 18-Fluorodeoxyglucose Positron Emission Tomography (PET) In the Pre-Operative Assessment of Patients With Hepatic Colorectal Metastases|
|Study Start Date :||July 1998|
|Actual Primary Completion Date :||March 2009|
|Actual Study Completion Date :||March 2009|
- To assess if whole body 18F-FDG-PET enhances our ability to detect metastatic colorectal cancer restricted to liver and lung over conventional imaging such as CT and to determine the accuracy of PET in imaging extrahepatic tumors. [ Time Frame: conclusion of the study ]
- To determine whether PET plays a role in altering clinical management of patients undergoing evaluation for liver resection for hepatic colorectal metastases. [ Time Frame: conclusion of the study ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00588549
|United States, New York|
|Memorial Sloan-Kettering Cancer Center|
|New York, New York, United States, 10065|
|Principal Investigator:||Yuman Fong, MD||Memorial Sloan Kettering Cancer Center|